HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide.
Screened 2026-09-07 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Heartflow, Inc. holds its Accumulation at $48.91. Consolidating, no directional conviction, held for 2 days.
As held on the ledger · 2026-09-07
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 2 days
Price at the screen
$48.91
Valuation
N/A trailing · -185.08 forward price to earnings
Values screen
PASS· score 97.3
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.79%
Below 33%
Interest-bearing debt is just 0.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.36%
Below 33%
Cash held in interest-bearing accounts and securities is 6.4% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades above our $45.00 fair value estimate, 47.60% revenue growth.
Fair value range in USD, drawn from the 2026-09-07 screen. The gold marker is the market price at the same screen. The price runs 8.0% above the base estimate.
Third-party analyst targets: 8 covering, consensus None. The average target sits −8% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-07 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
When a heart scan builds its own 3D map
Every time a cardiologist orders a CT scan instead of threading a catheter, HeartFlow turns raw images into a working model of blood flow. The platform sits at the centre of that shift, winning doctors with non-invasive precision while revenue climbs 41 percent. The shares trade at a 49 percent discount to our $37 fair value and the ethical screen clears without issue, yet the business still posts a 58 percent negative profit margin and a 135 percent negative return on equity.
Forward earnings sit at negative 94 times, which tells you the market is paying for future profits that have yet to appear. Seven analysts call it a strong buy with a $37 median target, lining up with our valuation, but those forecasts rest on rapid adoption that has not yet delivered black ink.
The real risk is simple execution. Heavy losses can linger if hospitals delay rollout or rivals copy the approach, and any slip in growth would widen the valuation gap quickly. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HTFL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-01Markup · changed$45.23+81.8%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 81.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (6 analysts) rates it buy, with a mean price target of $37.
2026-08-01Distribution$24.88-11.5%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (6 analysts) rates it buy, with a mean price target of $37.
2026-07-18Distribution$28.10+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (6 analysts) rates it buy, with a mean price target of $37.
2026-07-03Distribution$28.10+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$28.10Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.